» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing


More Information on Ethics and Clinical Trials

Letter in the Washington Post on Death of Jesse Gelsinger in Study

This letter, by Health Research Group Deputy Director Peter Lurie, M.D., MPH, appeared in the Washington Post on February 14, 2000.

The death of Jesse Gelsinger in the University of Pennsylvania gene therapy study raises the issue of reporting adverse events in clinical trials. Researchers are required to report adverse events in all clinical trials for experimental drugs to the Food and Drug Administration (FDA). Debate rages over whether gene therapy investigators should be required to report such events to the National Institutes of Health, which can disclose these events to the public, in addition to reporting them to the FDA, which cannot. This question evades the real issue: the failure of the FDA to disclose adverse events in all clinical trials. The FDA is charged with preserving the public health, not with protecting drug companies from investors who might desert them if they learned that an experimental drug "has some toxicity.  One cannot conduct quality or ethical research in an environment in which other scientists' experiences are hidden. Denying information can be hazardous; this may be the real lesson of the Gelsinger episode.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.